Naivek Participates in JP Morgan Healthcare... "Cancer Drug Research Presentation"

[Asia Economy Reporter Hyunseok Yoo] Naivek, a peptide fusion bio-specialized company, announced on the 6th that it will hold discussions related to its peptide drug delivery platform and major pipelines with global pharmaceutical companies at the '2021 JP Morgan Healthcare Conference.'

Naivek will participate in the '2021 JP Morgan Healthcare Conference,' held online from the 11th to the 14th (local time). At this conference, Naivek plans to present research results on the lung cancer-induced isograft tumor model of the 'K-RAS mutation inhibitor,' an anticancer drug based on the peptide drug delivery platform 'NIPEP-TPP' that it has been developing.

In addition, one-on-one corporate partnering sessions with major pharmaceutical companies will be conducted regarding research results on various pipelines, including oral and injectable formulations of osteoporosis treatments, pulmonary fibrosis treatments, and inflammatory bowel disease treatments.

A Naivek official stated, "We plan to conduct follow-up discussions and technical talks through corporate partnering with major pharmaceutical companies regarding Naivek's drug delivery platform NIPEP-TPP and various peptide-based pipelines," adding, "Since this conference is held online without spatial and temporal constraints, the actual persons in charge of each pipeline can directly participate in the meetings, which is expected to lead to more concrete discussions."

Naivek expects that through this conference, by conducting more detailed follow-up discussions with global big pharma companies with whom discussions have already been underway, it will be able to proceed with additional contracts with global pharmaceutical companies starting from this event.

This content was produced with the assistance of AI translation services.